Last reviewed · How we verify

Lysozyme hydrochloride — Competitive Intelligence Brief

Lysozyme hydrochloride (Lysozyme hydrochloride) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial enzyme. Area: Infectious Disease.

marketed Antimicrobial enzyme Peptidoglycan (bacterial cell wall component) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Lysozyme hydrochloride (Lysozyme hydrochloride) — Eisai Co., Ltd.. Lysozyme hydrochloride is an antimicrobial enzyme that breaks down bacterial cell walls by cleaving peptidoglycan, thereby killing bacteria and reducing infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lysozyme hydrochloride TARGET Lysozyme hydrochloride Eisai Co., Ltd. marketed Antimicrobial enzyme Peptidoglycan (bacterial cell wall component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial enzyme class)

  1. Eisai Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lysozyme hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/lysozyme-hydrochloride. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing